Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
NEW YORK, April 01, 2016 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Rockwell Medical, Inc. securities (NASDAQ:RMTI) from September 9, 2015 through February 29, 2016, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Rockwell Medical investors under the federal securities laws.
To join the Rockwell Medical class action, go to the firm’s website at http://rosenlegal.com/cases-847.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or email [email protected] or [email protected] for more information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) the primary product offering for Triferic will be in a powder packet packaging, which the FDA has not yet approved; (2) Rockwell Medical is seeking to obtain transitional add-on payment reimbursement for Triferic with the Centers for Medicare & Medicaid Services instead of bundled reimbursement; and (3) as a result, defendants’ statements about Rockwell Medical’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 3, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-847.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
